Ipragliflozin | B1926

Ipragliflozin is a potent inhibitor of sodium-glucose cotransporter 2 (SGLT2; IC₅₀ = 7.4 nM for human SGLT2 in vitro) that increases excretion of glucose.Iipragliflozin is found to promote preferential loss of fat mass in a rat model of non-obese type 2 diabetes mellitus (T2DM).

Ipragliflozin is a potent inhibitor of sodium-glucose cotransporter 2 (SGLT2; IC₅₀ = 7.4 nM for human SGLT2 in vitro) that increases excretion of glucose.Iipragliflozin is found to promote preferential loss of fat mass in a rat model of non-obese type 2 diabetes mellitus (T2DM).

B1926 | Ipragliflozin DataSheet

Alternate Name/Synonyms: (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 761423-87-4

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₁H₂₁FO₅S

Molecular Weight: 404.45

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~30 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent sodium-glucose cotransporter 2 (SGLT2) inhibitor

MDL Number: N/A

PubChem CID: 10453870

SMILES: C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)F

InChi: InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1

InChi Key: AHFWIQIYAXSLBA-RQXATKFSSA-N